It is also interesting that both anti-C3 and anti-C5 were given a label of ‘geographic atrophy’ despite the anti-C3 trials including both foveal and non-foveal involving lesions whilst in the anti-C5 trials, only non-foveal involving lesions were included. Here, C5 is linked to atrophic macular degeneration.